XGene Consulting exists because pharmaceutical CMC and quality-systems failures are rarely solved with better paperwork — they’re solved by people who have already lived through the failure mode from the inside.
Origin & Mission
Founded by Khaled Aamer, PhD, whose 20+ years span CMC and regulatory affairs roles at Amgen, Pfizer, Generation Bio, Pall/Danaher, and NIST, XGene has grown into a team of senior consultants with a combined 300+ years across CMC, quality, regulatory, and manufacturing leadership at organizations including Pfizer, Amgen, Moderna, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, and Zoetis.
That depth is documented, not asserted. Our technical writing program spans fifteen distinct regulatory and technical pillars — FDA enforcement and quality systems, biologics and BLA strategy, gene therapy, cell therapy, LNP/mRNA, sterile and injectable products, oral solid dosage, international regulatory CMC, and real-time regulatory intelligence among them — with more than fifty articles published to date against a mapped 365-article program. Every consultant on the team has run engagements matching that range: AI-driven CMC digital transformation, multi-site FDA Warning Letter remediation, Annex 1 compliance rollouts across global sterile networks. That range isn’t a marketing claim. It’s the working record of the problems we’ve actually been engaged to solve.
Our Team & Collective Expertise
XGene’s consultants have held VP Quality, SVP Technical Operations, and Associate Director roles inside the organizations that set the industry’s compliance bar — global sterile injectable networks, biologics process development groups, and combination-product quality functions at companies spanning Pfizer, Amgen, Moderna, Bristol Myers Squibb, Anthos Therapeutics, Immunovant, Sanofi, GlaxoSmithKline, Zoetis, and Perrigo. Individually, team members carry 19 to 40+ years of experience; collectively, the team represents more than 300 years inside regulated pharmaceutical manufacturing and quality organizations.
That experience spans six domains: CMC and regulatory strategy (IND/NDA/BLA/DMF authoring, Module 2/3 preparation, FDA and EMA meeting readiness); quality systems and compliance (FDA 483 and Warning Letter remediation, ALCOA+ data integrity programs, cGMP audits); aseptic and sterile manufacturing (Annex 1 gap assessments, sterilization validation, media fill and environmental monitoring programs); process development and technical operations (drug substance and drug product development, PPQ and process validation, CDMO oversight and tech transfer); combination products and devices (21 CFR Part 820 and ISO 13485 compliance, device history file and device master record review); and operational excellence (Lean Six Sigma deployment, batch release cycle time reduction, quality system transformation).
The depth of that experience shows up in the engagements themselves, not just the résumés: bringing six aseptic manufacturing sites to Voluntary Action Indicated status following FDA scrutiny, closing Annex 1 gaps across an entire multi-site sterile network, supporting a Phase III biotech’s drug substance and drug product PPQ campaigns ahead of BLA submission, reducing repeat deviations by more than 42% and clearing a 10,800-sample testing backlog in under five months at a commercial manufacturing site, and converting more than 200 legacy CMC authoring templates into AI-ready structured content for a top-10 pharmaceutical company. Regulatory reach extends across FDA (CDER and CBER), EMA, MHRA, Health Canada, TGA, PMDA, ANVISA, and MFDS.
How We Work
Every XGene engagement starts as a diagnostic, not a proposal. Before we recommend anything, we map the specific regulatory framework that actually governs the problem in front of us — the CFR subsection, the ICH guideline, the FDA compliance program manual — rather than starting from a generic best-practices template. A 483 response, an inspection-readiness review, or a Module 3 gap assessment is only as credible as the regulatory citation underneath it, and we build that citation trail first.
From there, we go past the cited observation to the management-system condition that produced it. A laboratory-controls finding, a data-integrity gap, or a specification deficiency is treated as a symptom until the root-cause analysis reaches at least three causal levels deep and lands on something structural — a missing escalation pathway, an audit trail that was never reviewed, a QTPP that was reverse-engineered from a finished formulation instead of built forward from patient need.
Engagements are staffed with the senior consultant whose background actually matches the problem — an aseptic Warning Letter remediation is led by someone who has personally carried VP Quality accountability for sterile injectable sites, not a generalist assigned after the sale. Depending on scope, that can mean a fixed-scope project, an embedded assessment, or fractional leadership sitting alongside an internal team for the duration of a remediation or submission program. The engagement model changes; the seniority of the person doing the work does not.
The deliverables reflect the same discipline throughout. Instead of a generic advisory deck, engagements produce named, structured frameworks — scoring matrices, traceability maps, phased readiness programs — where every commitment carries a specific completion date, a named owner, a measurable success criterion, and an independent effectiveness check. That’s the standard we hold client CAPAs to, and it’s the standard we apply to our own work.
Principles
Root cause, not procedural symptom-fixing. Human error is a conclusion that terminates an investigation, not a root cause. We treat every observation as a symptom until the analysis reaches the management-system condition that allowed it — a minimum of three causal levels, mapped back to the specific regulation cited.
Every claim traces to data. A specification, a CQA designation, or a QTPP element that can’t be traced back to its supporting dataset is an assertion, not a regulatory argument. We build our frameworks as traceability maps for this reason — QTPP to CQA to control strategy, deficiency to root cause to effectiveness check — so nothing in the final package is asserted rather than derived.
Precision over generic best practice. Every recommendation is anchored to the specific CFR subsection or ICH guideline behind it, and we say so plainly when a benchmark is practitioner convention rather than codified regulation. Generic “best practices” language doesn’t answer the only question that matters: what does the regulation actually require here.
Accountability that survives re-inspection. A commitment without a named owner, a specific completion date, a measurable success criterion, and an independent effectiveness check is an intention, not a corrective action. We hold every framework we build — and every engagement we run — to that same four-part test.